BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Bioxytran, Inc. BIXT
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD -0.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-532.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−9.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−11.5%
−9.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+11.0%
Change, 10 years—
The share count grew 11% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 658,552.00
total assets, end of FY2025
Total assetsUSD 658,552.00
Gross debtUSD 50,000.00
DepositsUSD 111,547.00
Current ratio0.16×
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
·
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
·
·
·
·
·
·
·
0.0
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.02
−0.02
−0.03
−0.02
−0.04
−0.03
−0.02
0.00
−0.01
−0.03
−0.21
−0.30
−0.47
−0.02
−0.06
−0.01
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
−828.2
−886.6
−8264.8
·
·
Shares out B
0.11
0.09
0.14
0.12
0.11
0.10
0.09
0.09
0.09
0.03
0.01
0.01
0.00
0.16
0.11
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed